Ying-Jie Wang, Kamayani Singh, Adam B. Lokman, Siwei Deng, Balaraju Sunitha, Jose Coelho Lima Jr., Julia Beglov, Matthew Kelly, Andrew Blease, Jacky C. K. Fung, Anan Huang, Moustafa Attar, Lee-Anne Stork, Mahon L. Maguire, Jürgen E. Schneider, Steve B. Marston, Elizabeth J. Soilleux, Calliope A. Dendrou, Mark Coles, Christopher D. Buckley, Jonathan G. Seidman, Christine E. Seidman, Charles Redwood, Houman Ashrafian, Hugh Watkins
{"title":"调节性T细胞减轻肥厚性心肌病的慢性炎症和心脏纤维化","authors":"Ying-Jie Wang, Kamayani Singh, Adam B. Lokman, Siwei Deng, Balaraju Sunitha, Jose Coelho Lima Jr., Julia Beglov, Matthew Kelly, Andrew Blease, Jacky C. K. Fung, Anan Huang, Moustafa Attar, Lee-Anne Stork, Mahon L. Maguire, Jürgen E. Schneider, Steve B. Marston, Elizabeth J. Soilleux, Calliope A. Dendrou, Mark Coles, Christopher D. Buckley, Jonathan G. Seidman, Christine E. Seidman, Charles Redwood, Houman Ashrafian, Hugh Watkins","doi":"10.1126/scitranslmed.adq3516","DOIUrl":null,"url":null,"abstract":"<div >Hypertrophic cardiomyopathy (HCM) is a common, serious, genetic heart muscle disorder. Although the biophysical mechanisms by which gene variants in sarcomeric proteins disrupt cardiomyocyte function are largely understood, the cellular and molecular pathways leading to the complex, variable, and adverse remodeling of the non-myocyte compartment are unexplained. Here, we report that postmortem and explanted human HCM hearts exhibited chronic focal leukocyte infiltration and prominent activation of immune cells. Gene set enrichment analysis (GSEA) revealed that active immune responses were present in the mid- and late-stage HCM human hearts and in mouse hearts from several HCM mouse models. The alpha cardiac actin 1-E99K (<i>Actc1</i><sup>E99K</sup>) HCM mouse model was selected for the study because it closely recapitulates the features of progressive remodeling and fibrosis seen in advanced disease in patients. Genetic depletion of lymphocytes in recombination activating gene 1–knockout (<i>Rag-1</i><sup>KO</sup>) mice led to marked exacerbation of adverse cardiac remodeling in the <i>Actc1</i><sup>E99K</sup> mice. Detailed characterization of cardiac regulatory T cells (T<sub>reg</sub> cells) demonstrated a time-dependent increase in <i>Actc1</i><sup>E99K</sup> hearts with altered immunosuppressive profiles. Adoptive transfer of splenic T<sub>reg</sub> cells reduced cardiac fibrosis and improved systolic dysfunction in <i>Actc1</i><sup>E99K</sup> mice with or without lymphocytes. In addition, low-dose interleukin-2 (IL-2)/anti–IL-2 complex (IL-2/c), which specifically induced T<sub>reg</sub> cell expansion in vivo, ameliorated cardiac fibrosis and reduced macrophage infiltration and activation in <i>Actc1</i><sup>E99K</sup> mice. These data contribute to our understanding of HCM and support the use of T<sub>reg</sub> cells as a clinically testable therapeutic strategy for cardiac fibrosis in the HCM heart.</div>","PeriodicalId":21580,"journal":{"name":"Science Translational Medicine","volume":"17 806","pages":""},"PeriodicalIF":15.8000,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Regulatory T cells attenuate chronic inflammation and cardiac fibrosis in hypertrophic cardiomyopathy\",\"authors\":\"Ying-Jie Wang, Kamayani Singh, Adam B. Lokman, Siwei Deng, Balaraju Sunitha, Jose Coelho Lima Jr., Julia Beglov, Matthew Kelly, Andrew Blease, Jacky C. K. Fung, Anan Huang, Moustafa Attar, Lee-Anne Stork, Mahon L. Maguire, Jürgen E. Schneider, Steve B. Marston, Elizabeth J. Soilleux, Calliope A. Dendrou, Mark Coles, Christopher D. Buckley, Jonathan G. Seidman, Christine E. Seidman, Charles Redwood, Houman Ashrafian, Hugh Watkins\",\"doi\":\"10.1126/scitranslmed.adq3516\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div >Hypertrophic cardiomyopathy (HCM) is a common, serious, genetic heart muscle disorder. Although the biophysical mechanisms by which gene variants in sarcomeric proteins disrupt cardiomyocyte function are largely understood, the cellular and molecular pathways leading to the complex, variable, and adverse remodeling of the non-myocyte compartment are unexplained. Here, we report that postmortem and explanted human HCM hearts exhibited chronic focal leukocyte infiltration and prominent activation of immune cells. Gene set enrichment analysis (GSEA) revealed that active immune responses were present in the mid- and late-stage HCM human hearts and in mouse hearts from several HCM mouse models. The alpha cardiac actin 1-E99K (<i>Actc1</i><sup>E99K</sup>) HCM mouse model was selected for the study because it closely recapitulates the features of progressive remodeling and fibrosis seen in advanced disease in patients. Genetic depletion of lymphocytes in recombination activating gene 1–knockout (<i>Rag-1</i><sup>KO</sup>) mice led to marked exacerbation of adverse cardiac remodeling in the <i>Actc1</i><sup>E99K</sup> mice. Detailed characterization of cardiac regulatory T cells (T<sub>reg</sub> cells) demonstrated a time-dependent increase in <i>Actc1</i><sup>E99K</sup> hearts with altered immunosuppressive profiles. Adoptive transfer of splenic T<sub>reg</sub> cells reduced cardiac fibrosis and improved systolic dysfunction in <i>Actc1</i><sup>E99K</sup> mice with or without lymphocytes. In addition, low-dose interleukin-2 (IL-2)/anti–IL-2 complex (IL-2/c), which specifically induced T<sub>reg</sub> cell expansion in vivo, ameliorated cardiac fibrosis and reduced macrophage infiltration and activation in <i>Actc1</i><sup>E99K</sup> mice. These data contribute to our understanding of HCM and support the use of T<sub>reg</sub> cells as a clinically testable therapeutic strategy for cardiac fibrosis in the HCM heart.</div>\",\"PeriodicalId\":21580,\"journal\":{\"name\":\"Science Translational Medicine\",\"volume\":\"17 806\",\"pages\":\"\"},\"PeriodicalIF\":15.8000,\"publicationDate\":\"2025-07-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Science Translational Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.science.org/doi/10.1126/scitranslmed.adq3516\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CELL BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Science Translational Medicine","FirstCategoryId":"3","ListUrlMain":"https://www.science.org/doi/10.1126/scitranslmed.adq3516","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CELL BIOLOGY","Score":null,"Total":0}
Regulatory T cells attenuate chronic inflammation and cardiac fibrosis in hypertrophic cardiomyopathy
Hypertrophic cardiomyopathy (HCM) is a common, serious, genetic heart muscle disorder. Although the biophysical mechanisms by which gene variants in sarcomeric proteins disrupt cardiomyocyte function are largely understood, the cellular and molecular pathways leading to the complex, variable, and adverse remodeling of the non-myocyte compartment are unexplained. Here, we report that postmortem and explanted human HCM hearts exhibited chronic focal leukocyte infiltration and prominent activation of immune cells. Gene set enrichment analysis (GSEA) revealed that active immune responses were present in the mid- and late-stage HCM human hearts and in mouse hearts from several HCM mouse models. The alpha cardiac actin 1-E99K (Actc1E99K) HCM mouse model was selected for the study because it closely recapitulates the features of progressive remodeling and fibrosis seen in advanced disease in patients. Genetic depletion of lymphocytes in recombination activating gene 1–knockout (Rag-1KO) mice led to marked exacerbation of adverse cardiac remodeling in the Actc1E99K mice. Detailed characterization of cardiac regulatory T cells (Treg cells) demonstrated a time-dependent increase in Actc1E99K hearts with altered immunosuppressive profiles. Adoptive transfer of splenic Treg cells reduced cardiac fibrosis and improved systolic dysfunction in Actc1E99K mice with or without lymphocytes. In addition, low-dose interleukin-2 (IL-2)/anti–IL-2 complex (IL-2/c), which specifically induced Treg cell expansion in vivo, ameliorated cardiac fibrosis and reduced macrophage infiltration and activation in Actc1E99K mice. These data contribute to our understanding of HCM and support the use of Treg cells as a clinically testable therapeutic strategy for cardiac fibrosis in the HCM heart.
期刊介绍:
Science Translational Medicine is an online journal that focuses on publishing research at the intersection of science, engineering, and medicine. The goal of the journal is to promote human health by providing a platform for researchers from various disciplines to communicate their latest advancements in biomedical, translational, and clinical research.
The journal aims to address the slow translation of scientific knowledge into effective treatments and health measures. It publishes articles that fill the knowledge gaps between preclinical research and medical applications, with a focus on accelerating the translation of knowledge into new ways of preventing, diagnosing, and treating human diseases.
The scope of Science Translational Medicine includes various areas such as cardiovascular disease, immunology/vaccines, metabolism/diabetes/obesity, neuroscience/neurology/psychiatry, cancer, infectious diseases, policy, behavior, bioengineering, chemical genomics/drug discovery, imaging, applied physical sciences, medical nanotechnology, drug delivery, biomarkers, gene therapy/regenerative medicine, toxicology and pharmacokinetics, data mining, cell culture, animal and human studies, medical informatics, and other interdisciplinary approaches to medicine.
The target audience of the journal includes researchers and management in academia, government, and the biotechnology and pharmaceutical industries. It is also relevant to physician scientists, regulators, policy makers, investors, business developers, and funding agencies.